Apogee Therapeutics, Inc. (NASDAQ:APGE – Get Free Report) fell 7.8% on Thursday . The company traded as low as $44.50 and last traded at $44.98. 629,892 shares changed hands during mid-day trading, an increase of 25% from the average session volume of 502,104 shares. The stock had previously closed at $48.77.
Analysts Set New Price Targets
A number of equities research analysts recently commented on APGE shares. Guggenheim reiterated a “buy” rating on shares of Apogee Therapeutics in a research report on Thursday. Canaccord Genuity Group started coverage on Apogee Therapeutics in a research report on Monday, November 25th. They issued a “buy” rating and a $89.00 target price on the stock. Canaccord Genuity Group started coverage on Apogee Therapeutics in a research report on Monday, November 25th. They issued a “buy” rating and a $89.00 target price on the stock. Finally, Wedbush boosted their target price on Apogee Therapeutics from $87.00 to $90.00 and gave the stock an “outperform” rating in a research report on Monday, December 2nd. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Apogee Therapeutics presently has an average rating of “Buy” and an average price target of $83.88.
View Our Latest Research Report on Apogee Therapeutics
Apogee Therapeutics Price Performance
Insider Buying and Selling at Apogee Therapeutics
In other news, CEO Michael Thomas Henderson sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $46.58, for a total transaction of $698,700.00. Following the transaction, the chief executive officer now owns 1,324,487 shares of the company’s stock, valued at approximately $61,694,604.46. This represents a 1.12 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Carl Dambkowski sold 4,540 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $48.76, for a total value of $221,370.40. Following the transaction, the insider now directly owns 258,073 shares in the company, valued at approximately $12,583,639.48. This represents a 1.73 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 94,535 shares of company stock worth $5,133,635 over the last ninety days. Company insiders own 36.10% of the company’s stock.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the business. Point72 DIFC Ltd bought a new position in Apogee Therapeutics in the second quarter worth approximately $660,000. Point72 Asset Management L.P. grew its stake in Apogee Therapeutics by 162.7% in the third quarter. Point72 Asset Management L.P. now owns 707,268 shares of the company’s stock worth $41,545,000 after purchasing an additional 438,036 shares in the last quarter. XTX Topco Ltd bought a new position in Apogee Therapeutics in the second quarter worth approximately $706,000. Victory Capital Management Inc. grew its stake in Apogee Therapeutics by 56.8% in the second quarter. Victory Capital Management Inc. now owns 156,266 shares of the company’s stock worth $6,149,000 after purchasing an additional 56,607 shares in the last quarter. Finally, Waypoint Capital Advisors LLC bought a new position in Apogee Therapeutics in the third quarter worth approximately $36,835,000. Institutional investors own 79.04% of the company’s stock.
Apogee Therapeutics Company Profile
Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.
Further Reading
- Five stocks we like better than Apogee Therapeutics
- 10 Best Airline Stocks to Buy
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- How to Calculate Inflation Rate
- Texas Instruments: The Old-School Tech Titan Still Delivering
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- GRAIL: Biotech Stock Targeting $100B Cancer Market
Receive News & Ratings for Apogee Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apogee Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.